Zhaoxue Lu1,3,*, Ying Li2,3, Xuguang Zhang2,3
1Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
2Department of Radiation Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China.
3First Clinical College, Xuzhou Medicine University, Xuzhou, Jiangsu, China.
*Corresponding author: Zhaoxue Lu
 Siegel, R.L., et al., Cancer statistics, 2022. CA Cancer J Clin, 2022. 72(1): p. 7-33.
 Govindan, R., et al., Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006. 24(28): p. 4539-44.
 Zelen, M., Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3, 1973. 4(2): p. 31-42.
 Kalemkerian, G.P., Small Cell Lung Cancer. Semin Respir Crit Care Med, 2016. 37(5): p. 783-796.
 Mansfield, A.S., et al., Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol, 2020. 31(2): p. 310-317.
 Paz-Ares, L., et al., Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, 2019. 394(10212): p. 1929-1939.
 Nishino, M., et al., Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol, 2017. 14(11): p. 655-668.
 Rathore, A.S., et al., CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res, 2014. 140(3): p. 361-9.
 Chen, Y., et al., Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer. Cancer Immunol Immunother, 2021. 70(10): p. 2867-2876.
 Sun, C., et al., Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer. Onco Targets Ther, 2020. 13: p. 6475-6483.
 Kamphorst, A.O., et al., Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A, 2017. 114(19): p. 4993-4998.
 Huang, A.C., et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017. 545(7652): p. 60-65.
 Miao, K., et al., Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Front Immunol, 2022. 13: p. 912180.